- Home
- NTRB vs MIST Comparison
NTRB vs MIST Comparison
Compare NTRB & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRB
- MIST
- Stock Information
- Founded
- NTRB 2016
- MIST 2003
- Country
- NTRB United States
- MIST Canada
- Employees
- NTRB N/A
- MIST N/A
- Industry
- NTRB Industrial Specialties
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- NTRB Health Care
- MIST Health Care
- Exchange
- NTRB Nasdaq
- MIST Nasdaq
- Market Cap
- NTRB 77.9M
- MIST 81.5M
- IPO Year
- NTRB N/A
- MIST N/A
- Fundamental
- Price
- NTRB $6.17
- MIST $1.43
- Analyst Decision
- NTRB
- MIST Strong Buy
- Analyst Count
- NTRB 0
- MIST 3
- Target Price
- NTRB N/A
- MIST $13.00
- AVG Volume (30 Days)
- NTRB 28.2K
- MIST 177.8K
- Earning Date
- NTRB 12-11-2024
- MIST 11-11-2024
- Dividend Yield
- NTRB N/A
- MIST N/A
- EPS Growth
- NTRB N/A
- MIST N/A
- EPS
- NTRB N/A
- MIST N/A
- Revenue
- NTRB $1,803,816.00
- MIST N/A
- Revenue This Year
- NTRB N/A
- MIST N/A
- Revenue Next Year
- NTRB N/A
- MIST N/A
- P/E Ratio
- NTRB N/A
- MIST N/A
- Revenue Growth
- NTRB N/A
- MIST N/A
- 52 Week Low
- NTRB $1.93
- MIST $1.12
- 52 Week High
- NTRB $9.60
- MIST $3.52
- Technical
- Relative Strength Index (RSI)
- NTRB 50.57
- MIST 42.50
- Support Level
- NTRB $5.24
- MIST $1.41
- Resistance Level
- NTRB $6.40
- MIST $1.53
- Average True Range (ATR)
- NTRB 0.71
- MIST 0.07
- MACD
- NTRB -0.12
- MIST -0.01
- Stochastic Oscillator
- NTRB 33.23
- MIST 26.96
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).